Abstract
Designing optimal, Bayesian decision-theoretic trials has traditionally required the use of computationally-intensive backward induction. While methods for addressing this barrier have been put forward, few are both computationally tractable and non-myopic, with applications of the Gittins index being one notable example. Here we explore the look-ahead approach with adaptive-randomization, with designs ranging from the fully myopic to the fully informed. We compare the operating characteristics of the look-ahead designed trials, in which decision rules are based on a fixed number of future blocks, with those of trials designed using traditional backward induction. The less-myopic designs performed well. As the designs become more myopic or the trials longer, there were disparities in regions of the decision space that are transition zones between continuation and stopping decisions. The more myopic trials generally suffered from early stopping as compared to the less myopic and backward induction trials. Myopic trials with adaptive randomization also saw as many as 28 % of their continuation decisions change to a different randomization ratio as compared to the backward induction designs. Finally, early stages of myopic-designed trials may have disproportionate effect on trial characteristics.
Funding statement: This work was supported by National Center for Research Resources, Funder Id: 10.13039/100000097, Grant Number: 1F32RR022167
References
[1] DeGroot MH. Optimal statistical decisions. New York: McGraw-Hill; 1970. p. 267–323.Search in Google Scholar
[2] Carlin BP, Kadane JB, Gelfand AE. Approaches for optimal sequential decision analysis in clinical trials. Biometrics. 1998;54:964–75.10.2307/2533849Search in Google Scholar
[3] Brockwell AE, Kadane JB. A gridding method for Bayesian sequential decision problems. J Comput Graph Stat. 2003;12:566–84.10.1198/1061860032274Search in Google Scholar
[4] Müller P, Berry DA, Grieve AP, Smith M, Krams M. Simulation-based sequential Bayesian design. J Stat Plan Inference. 2007;137:3140–50.10.1016/j.jspi.2006.05.021Search in Google Scholar
[5] Cheng Y, Shen Y. Bayesian adaptive designs for clinical trials. Biometrika. 2005;92:633–46.10.1093/biomet/92.3.633Search in Google Scholar
[6] Lewis RJ, Lipsky AM, Berry DA. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation. Clin Trials. 2007;4:5–14.10.1177/1740774506075764Search in Google Scholar PubMed
[7] Berry DA, Ho CH. One-sided sequential stopping boundaries for clinical trials: a decision-theoretic approach. Biometrics. 1988;44:219–27.10.2307/2531909Search in Google Scholar
[8] Lewis RJ, Berry DA. Group sequential clinical trials: a classical evaluation of Bayesian decision-theoretic designs. J Am Stat Assoc. 1994;89:1528–34.10.1080/01621459.1994.10476893Search in Google Scholar
[9] Gittins J, Jones D. A dynamic allocation index for the discounted multiarmed bandit problem. Biometrika. 1979;66:561–5.10.1093/biomet/66.3.561Search in Google Scholar
[10] Villar SS, Wason J, Bowden J. Response-adaptive randomization for multi-arm clinical trials using the forward looking Gittins index rule. Biometrics. 2015;71:969–78.10.1111/biom.12337Search in Google Scholar PubMed PubMed Central
[11] Villar SS, Rosenberger WF. Covariate‐adjusted response‐adaptive randomization for multi‐arm clinical trials using a modified forward looking Gittins index rule. Biometrics. 2018;74:49–57.10.1111/biom.12738Search in Google Scholar PubMed PubMed Central
[12] Rossell D, Müller P, Rosner GL. Screening designs for drug development. Biostat. 2007;8:595–608.10.1093/biostatistics/kxl031Search in Google Scholar PubMed
[13] Stallard N, Thall PF. Decision-theoretic designs for pre-phase II screening trials in oncology. Biometrics. 2001;57:1089–95.10.1111/j.0006-341X.2001.01089.xSearch in Google Scholar PubMed
[14] Berger JO. Statistical Decision Theory and Bayesian Analysis, Seconded.New York: Springer-Verlag, ch. 7, 1985.10.1007/978-1-4757-4286-2Search in Google Scholar
[15] Christen JA, Müller P, Wathen K, Wolf J. Bayesian randomized clinical trials: a decision-theoretic sequential design. Can J Stat. 2004;32:387–402.10.2307/3316023Search in Google Scholar
[16] Lipsky AM, Lewis RJ. Response-adaptive decision-theoretic trial design: operating characteristics and ethics. Stat Med. 2013;32:3752–65.10.1002/sim.5807Search in Google Scholar PubMed PubMed Central
[17] Ding M, Rosner GL, Müller P. Bayesian optimal design for phase II screening trials. Biometrics. 2008;64:886–94.10.1111/j.1541-0420.2007.00951.xSearch in Google Scholar PubMed PubMed Central
© 2019 Walter de Gruyter GmbH, Berlin/Boston
